137 related articles for article (PubMed ID: 37657236)
21. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
[TBL] [Abstract][Full Text] [Related]
22. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40.
Hamano R; Huang J; Yoshimura T; Oppenheim JJ; Chen X
Eur J Immunol; 2011 Jul; 41(7):2010-20. PubMed ID: 21491419
[TBL] [Abstract][Full Text] [Related]
23. Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.
Verwoerd A; Hijdra D; Vorselaars AD; Crommelin HA; van Moorsel CH; Grutters JC; Claessen AM
Clin Exp Immunol; 2016 Aug; 185(2):263-70. PubMed ID: 27158798
[TBL] [Abstract][Full Text] [Related]
24. Topical Application of Tetrandrine Nanoemulsion Promotes the Expansion of CD4
Chen S; Lin Z; He T; Islam MS; Xi L; Liao P; Yang Y; Zheng Y; Chen X
Front Immunol; 2022; 13():800283. PubMed ID: 35464441
[TBL] [Abstract][Full Text] [Related]
25. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
[TBL] [Abstract][Full Text] [Related]
26. Regulatory T cell induction by mesenchymal stem cells depends on the expression of TNFR2 by T cells.
Naserian S; Shamdani S; Arouche N; Uzan G
Stem Cell Res Ther; 2020 Dec; 11(1):534. PubMed ID: 33303019
[TBL] [Abstract][Full Text] [Related]
27. Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients.
Yip WK; Abdullah MA; Yusoff SM; Seow HF
Clin Exp Immunol; 2009 Mar; 155(3):412-22. PubMed ID: 19220831
[TBL] [Abstract][Full Text] [Related]
28. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
Govindaraj C; Tan P; Walker P; Wei A; Spencer A; Plebanski M
Clin Cancer Res; 2014 Feb; 20(3):724-35. PubMed ID: 24297862
[TBL] [Abstract][Full Text] [Related]
29. Reduced frequency and functional defects of CD4
Luo L; Zeng X; Huang Z; Luo S; Qin L; Li S
Reprod Biol Endocrinol; 2020 Jun; 18(1):62. PubMed ID: 32522204
[TBL] [Abstract][Full Text] [Related]
30. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
Liao P; Jiang M; Islam MS; Wang Y; Chen X
Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
[TBL] [Abstract][Full Text] [Related]
31. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells.
Kakita N; Kanto T; Itose I; Kuroda S; Inoue M; Matsubara T; Higashitani K; Miyazaki M; Sakakibara M; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
Int J Cancer; 2012 Dec; 131(11):2573-83. PubMed ID: 22419479
[TBL] [Abstract][Full Text] [Related]
32. Bivalent structure of a TNFR2-selective and agonistic TNF-α mutein Fc-fusion protein enhances the expansion activity of regulatory T cells.
Inoue M; Tsuji Y; Ueno R; Miyamoto D; Tanaka K; Moriyasu Y; Shibata S; Okuda M; Ando D; Abe Y; Kamada H; Tsunoda SI
Sci Rep; 2023 Aug; 13(1):13762. PubMed ID: 37612373
[TBL] [Abstract][Full Text] [Related]
33. Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice.
Pan XD; Mao YQ; Zhu LJ; Li J; Xie Y; Wang L; Zhang GB
Chin Med J (Engl); 2012 Jun; 125(11):2004-11. PubMed ID: 22884069
[TBL] [Abstract][Full Text] [Related]
34. Expression and function of TNF and IL-1 receptors on human regulatory T cells.
Mercer F; Kozhaya L; Unutmaz D
PLoS One; 2010 Jan; 5(1):e8639. PubMed ID: 20066156
[TBL] [Abstract][Full Text] [Related]
35. Paeoniflorin ameliorates murine lupus nephritis by increasing CD4
Liang CL; Lu W; Qiu F; Li D; Liu H; Zheng F; Zhang Q; Chen Y; Lu C; Li B; Dai Z
Biochem Pharmacol; 2021 Mar; 185():114434. PubMed ID: 33513343
[TBL] [Abstract][Full Text] [Related]
36. CD45RA-Foxp3high but not CD45RA+Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression.
Sun W; Li WJ; Wu CY; Zhong H; Wen WP
J Exp Clin Cancer Res; 2014 Apr; 33(1):35. PubMed ID: 24761979
[TBL] [Abstract][Full Text] [Related]
37. Progranulin promotes tumour necrosis factor-induced proliferation of suppressive mouse CD4⁺ Foxp3⁺ regulatory T cells.
Hu Y; Xiao H; Shi T; Oppenheim JJ; Chen X
Immunology; 2014 Jun; 142(2):193-201. PubMed ID: 24383743
[TBL] [Abstract][Full Text] [Related]
38. [The decreased proportion of CD4
Yang D; Wu M
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Sep; 38(9):831-836. PubMed ID: 36082714
[TBL] [Abstract][Full Text] [Related]
39. Spatial architecture of regulatory T-cells correlates with disease progression in patients with nasopharyngeal cancer.
Zhou F; Shayan G; Sun S; Huang X; Chen X; Wang K; Qu Y; Wu R; Zhang Y; Liu Q; Zhang J; Luo J; Shi X; Liu Y; Liang B; Li YX; Wang J; Yi J
Front Immunol; 2022; 13():1015283. PubMed ID: 36439177
[TBL] [Abstract][Full Text] [Related]
40. CD4+CD25+CD127-Foxp3+ and CD8+CD28- Tregs in Renal Transplant Recipients: Phenotypic Patterns, Association With Immunosuppressive Drugs, and Interaction With Effector CD8+ T Cells and CD19+IL-10+ Bregs.
Aly MG; Ibrahim EH; Karakizlis H; Weimer R; Opelz G; Morath C; Zeier M; Ekpoom N; Daniel V
Front Immunol; 2021; 12():716559. PubMed ID: 34335631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
